Introduction: Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance. Methods: Data were obtained from ICUs between 2010 and 2013. Results: P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B. Conclusions: Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial-and multidrug resistance.
CITATION STYLE
Ribeiro, Á. C. da S., Crozatti, M. T. L., da Silva, A. A., Macedo, R. S., Machado, A. M. de O., & Silva, A. T. de A. (2020). Pseudomonas aeruginosa in the ICU: Prevalence, resistance profile, and antimicrobial consumption. Revista Da Sociedade Brasileira de Medicina Tropical, 53. https://doi.org/10.1590/0037-8682-0498-2018
Mendeley helps you to discover research relevant for your work.